# Carotid Body Tumors and Paragangliomas ## Overview Carotid body tumors (CBTs) are paragangliomas that originate from chemoreceptor cells located at the carotid bifurcation. They represent the most common type of head and neck paraganglioma, accounting for 60-70% of all cervicocephalic paragangliomas. These tumors typically grow slowly and are benign in nature, with a malignancy rate estimated between 5-10%. Bilaterality occurs in about 5% of sporadic cases but is much more common in familial cases, where it can reach 30-40%. Surgical resection remains the primary treatment modality, although it can be technically challenging due to the tumor’s tendency to encase carotid vessels and cranial nerves. ## Anatomy and Pathology ### Carotid Body The carotid body is a small chemoreceptor organ, measuring approximately 3-5 mm, situated in the adventitia at the carotid bifurcation. It functions to sense changes in blood oxygen, carbon dioxide, and pH levels. Embryologically, it is derived from neural crest cells, classifying it as part of the paraganglia. Its blood supply primarily arises from feeding vessels branching off the external carotid artery, most notably the ascending pharyngeal artery. ### Paraganglioma Biology Paragangliomas arise from chief cells, also known as type I cells, within the paraganglia. These neuroendocrine tumors may produce catecholamines, although only 1-3% are functional in this regard. They exhibit a slow growth rate, averaging 1-2 mm per year. Malignancy in paragangliomas is defined by the presence of metastasis rather than histologic features, with an overall rate of 5-10%. Several genetic syndromes are associated with these tumors, including mutations in the succinate dehydrogenase (SDH) genes—SDHB, SDHC, and SDHD—as well as multiple endocrine neoplasia type 2 (MEN2), neurofibromatosis type 1 (NF1), and von Hippel-Lindau disease (VHL). Among these, SDHB mutations carry the highest risk of malignancy, estimated at 30-40%. ### Other Cervicocephalic Paragangliomas Other paragangliomas in the head and neck region include the glomus jugulare, located at the jugular foramen; the glomus tympanicum, found in the middle ear; and the glomus vagale, which arises along the cervical vagus nerve. These tumors may occur in association with carotid body tumors, resulting in multicentric paragangliomas. ## Shamblin Classification The Shamblin classification system categorizes carotid body tumors based on their size and relationship to the carotid vessels. Type I tumors are small and localized, easily dissected from the vessels with minimal attachment to the carotid wall, and are associated with low surgical morbidity. Type II tumors are of moderate size and partially encase the carotid vessels, adhering to the adventitia and requiring careful subadventitial dissection; this is the most common presentation. Type III tumors are large and completely encase the carotid bifurcation, often necessitating carotid resection and reconstruction, and carry the highest risk of cranial nerve injury and stroke. | Shamblin Type | Size | Vessel Involvement | Surgical Difficulty | Complications | |---------------|------|-------------------|--------------------|----| | I | Small | Minimal attachment; easily dissected from vessels | Low | Low cranial nerve injury risk | | II | Moderate | Partially encases carotid arteries; adherent to adventitia | Moderate (subadventitial dissection required) | Moderate; most common presentation | | III | Large | Completely encases ICA and ECA | High; often requires carotid resection + reconstruction | Highest stroke (up to 5%) and CN injury (20-40%) risk | Shamblin classification diagram showing Type I (small tumor splaying the carotid bifurcation), Type II (partially encasing the carotid arteries), and Type III (completely encasing the internal and external carotid arteries) ## Clinical Presentation Patients with carotid body tumors typically present with a painless, slowly enlarging neck mass located at the angle of the mandible. The mass is firm and pulsatile, exhibiting mobility in the horizontal plane but not vertically, a clinical feature known as the Fontaine sign. Transmitted carotid pulsation is often palpable, and occasionally a bruit may be auscultated. Larger tumors can cause cranial nerve deficits, particularly involving cranial nerves X (vagus), XII (hypoglossal), IX (glossopharyngeal), and the marginal mandibular branch of VII (facial nerve). Advanced cases may present with dysphagia, hoarseness, or Horner syndrome. Functional tumors, which constitute less than 3% of cases, may cause systemic symptoms such as hypertension, tachycardia, headache, and flushing; in these cases, 24-hour urine catecholamines and metanephrines should be measured. When bilateral tumors are identified, screening of family members and genetic testing are recommended. ## Diagnosis ### Imaging Computed tomography angiography (CTA) is the primary diagnostic study for carotid body tumors. It reveals an intensely enhancing mass at the carotid bifurcation and demonstrates the characteristic "lyre sign," which is the splaying of the internal and external carotid arteries. CTA also provides detailed information about tumor size, its relationship to the carotid vessels, and the status of the contralateral carotid artery. Magnetic resonance angiography (MRA) offers excellent tumor characterization without radiation exposure, showing a distinctive "salt and pepper" appearance on T1- and T2-weighted images, where flow voids represent the "pepper" and hemorrhage or slow flow corresponds to the "salt." Catheter angiography is generally reserved for preoperative embolization planning, allowing visualization of tumor blush, feeding vessels, and carotid encasement. Positron emission tomography/computed tomography (PET/CT) using gallium-68 DOTATATE is superior to FDG-PET for detecting paragangliomas, identifying multifocal disease, metastases, and occult tumors. This modality is particularly recommended for patients with SDH mutations for whole-body screening. ### Laboratory Laboratory evaluation includes 24-hour urine metanephrines and catecholamines to rule out functional tumors. Plasma free metanephrines serve as an alternative. It is critical to perform these tests before any biopsy or surgical intervention because functional tumors require preoperative alpha-blockade to prevent hypertensive crises. ### Genetic Testing Genetic testing is recommended for all patients diagnosed with paragangliomas. Testing focuses on mutations in SDH subunits (SDHA, SDHB, SDHC, SDHD, SDHAF2). Identifying these mutations has important implications for screening family members, surveillance for multicentric or multisystem disease, and malignancy risk stratification. ### Biopsy Biopsy is not recommended due to the highly vascular nature of these tumors and the significant risk of bleeding. Diagnosis is primarily clinical and radiographic, with tissue confirmation obtained at the time of surgical resection. CT angiography showing a large carotid body tumor with intense contrast enhancement at the carotid bifurcation demonstrating the characteristic "lyre sign" with splaying of the internal and external carotid arteries ## Treatment ### Surgical Resection #### Indications Surgical resection is indicated for symptomatic tumors, tumors demonstrating growth during surveillance, young and fit patients given the likelihood of continued tumor growth over their lifetime, and functional tumors after appropriate medical preparation. #### Preoperative Considerations Preoperative planning involves cross-sectional imaging to delineate tumor anatomy and assess the contralateral carotid artery. For functional tumors, alpha-blockade with phenoxybenzamine is administered for 10-14 days preoperatively, followed by beta-blockade and adequate volume expansion. Blood products should be readily available due to the potential for significant hemorrhage. Neuromonitoring of the vagus and hypoglossal nerves may be considered, along with electroencephalography (EEG) or cerebral oximetry during carotid clamping to monitor cerebral perfusion. #### Preoperative Embolization Selective embolization of tumor feeding vessels is performed 24-48 hours before surgery via branches of the external carotid artery such as the ascending pharyngeal or occipital arteries. Embolization agents include polyvinyl alcohol (PVA) particles, microspheres, and coils. This procedure reduces intraoperative blood loss, particularly in Shamblin II and III tumors. However, its use remains controversial, as some surgeons find it unnecessary for smaller tumors (Shamblin I-II), and embolization carries risks of stroke and cranial nerve injury. #### Surgical Technique The surgical approach involves an incision along the anterior border of the sternocleidomastoid muscle. Cranial nerves including the vagus, hypoglossal, glossopharyngeal, superior laryngeal, and marginal mandibular branches are identified and protected. Proximal and distal control of the internal carotid artery (ICA), external carotid artery (ECA), and common carotid artery (CCA) is obtained. The tumor arises from the adventitia, so dissection proceeds in the subadventitial plane between the tumor capsule and vessel wall. Feeding vessels from the ECA are ligated as encountered. Dissection continues from the CCA superiorly, ICA laterally, and ECA medially. For Shamblin III tumors, resection of the ECA is often acceptable, while ICA resection requires interposition grafting, typically using vein or polytetrafluoroethylene (PTFE), with consideration of a shunt during clamping. Hemostasis is achieved through bipolar cautery, topical hemostatic agents, and meticulous surgical technique. #### Complications Cranial nerve injury occurs in 20-40% of cases, most commonly affecting the vagus (X) and hypoglossal (XII) nerves. Vagal nerve injury leads to hoarseness due to recurrent laryngeal nerve involvement, while hypoglossal nerve injury causes tongue deviation and dysarthria. Most nerve injuries are neuropraxias and recover over weeks to months. Stroke occurs in 1-5% of cases, with higher rates in Shamblin III tumors. Other complications include hemorrhage and first bite syndrome, characterized by pain in the parotid region with the first bite of each meal due to sympathetic denervation of the parotid gland. Loss of carotid body function is usually asymptomatic when unilateral, but bilateral resection may impair chemoreceptor function. ### Radiation Therapy Radiation therapy is not curative but can halt tumor growth, achieving tumor control rates of 90-95% at 5-10 years. It is indicated for surgically unresectable tumors, elderly or frail patients unfit for surgery, residual or recurrent disease after surgery, and bilateral tumors where staged surgery is performed on one side and radiation on the other. Techniques include stereotactic radiosurgery (Gamma Knife, CyberKnife) and intensity-modulated radiation therapy (IMRT). Late complications may include carotid stenosis, cranial nerve damage, and secondary malignancy. ### Observation/Surveillance Observation is reasonable for small, asymptomatic tumors in elderly patients. Annual imaging is recommended to monitor tumor growth, which typically progresses at a rate of 1-2 mm per year. Many tumors remain indolent for years. ## Bilateral Carotid Body Tumors In cases of bilateral carotid body tumors, staged surgical resection is performed 6-12 months apart to reduce the risk of bilateral cranial nerve injury, particularly vagus nerve damage, which can cause bilateral vocal cord paralysis and airway compromise. Radiation therapy may be considered for the contralateral tumor if surgical risk is prohibitive. The larger or more symptomatic tumor is resected first. Intraoperative photograph showing surgical resection of a carotid body tumor with identification of the internal carotid artery, external carotid artery, and hypoglossal nerve, demonstrating the subadventitial dissection plane ## Clinical Pearls A painless, pulsatile neck mass located at the angle of the mandible that is mobile horizontally but not vertically should be considered a carotid body tumor until proven otherwise, and biopsy should be avoided due to bleeding risk. It is essential to check urine catecholamines and metanephrines before any intervention because functional paragangliomas require alpha-blockade prior to surgery to prevent hypertensive crises. Genetic testing should be offered to all patients with paragangliomas, as up to 40% harbor germline SDH mutations, with SDHB mutation carriers having a significantly higher risk of malignancy. The key to safe surgical resection lies in maintaining the subadventitial plane, staying on the tumor capsule, and carefully peeling it off the arterial wall. Sacrifice of the external carotid artery is acceptable and often necessary for Shamblin III tumors, while internal carotid artery reconstruction is mandatory if the ICA must be resected. Preoperative embolization remains controversial; although it may reduce blood loss for large tumors, it carries risks of stroke and cranial nerve injury. After bilateral carotid body tumor resection, patients may lose their hypoxic drive, which is important to consider for anesthetic management and long-term care. ## References - Shamblin WR, et al. Carotid body tumor (chemodectoma): clinicopathologic analysis of ninety cases. *Am J Surg*. 1971;122(6):732-739. - Lim JY, et al. Current management of carotid body tumors. *Ann Vasc Surg*. 2010;24(5):690-696. - Corssmit EPM, et al. Clinical management of paragangliomas. *Eur J Endocrinol*. 2020;183(3):R95-R109. - Power AH, et al. Impact of preoperative embolization on outcomes of carotid body tumor resection. *J Vasc Surg*. 2012;56(4):979-989. - Neumann HPH, et al. Pheochromocytoma and paraganglioma. *N Engl J Med*. 2019;381(6):552-565.